GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » Revenue

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Revenue : ¥1,339 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co Revenue?

Zhejiang East-Asia Pharmaceutical Co's revenue for the three months ended in Mar. 2024 was ¥353 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,339 Mil. Zhejiang East-Asia Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥2.35. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥10.09.

Warning Sign:

Zhejiang East-Asia Pharmaceutical Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Zhejiang East-Asia Pharmaceutical Co was -10.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 2.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Zhejiang East-Asia Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 8.40% per year. The lowest was -14.60% per year. And the median was 2.50% per year.


Zhejiang East-Asia Pharmaceutical Co Revenue Historical Data

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang East-Asia Pharmaceutical Co Revenue Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 988.09 881.67 712.22 1,179.56 1,356.45

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 369.70 304.48 330.32 351.96 352.58

Competitive Comparison of Zhejiang East-Asia Pharmaceutical Co's Revenue

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang East-Asia Pharmaceutical Co's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Revenue falls into.



Zhejiang East-Asia Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,339 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang East-Asia Pharmaceutical Co  (SHSE:605177) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Zhejiang East-Asia Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Business Description

Traded in Other Exchanges
N/A
Address
Laodong North Road, 23rd Floor, General Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Headlines

No Headlines